Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials

Maturitas

Volumn 34, Issue 1, 2000, Pages 65-73

  Cohen, Fredric J ^a   Lu, Yili ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Hot flashes; Osteoporosis; Prevention; Raloxifene; SERM; Side effects; Vasodilatation

Indexed keywords

CALCIUM; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; FEMALE; HOT FLUSH; HUMAN; HYSTERECTOMY; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; VASODILATATION;

ADULT; DOUBLE-BLIND METHOD; ESTROGEN ANTAGONISTS; FEMALE; HOT FLASHES; HUMANS; INCIDENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 0034650419     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(99)00090-0     Document Type: Article

References (40)

1. Kronenberg F. Hot flashes. Lobo R.A. Treatment of the Postmenopausal Woman: Basic and Clinical Aspects. 1994;97-117 Raven Press, New York.
2. Schiff I., Regestein Q., Tulchinsky D., Ryan K.J. Effects of estrogens on sleep and psychological state of hypogonadal women. J. Am. Med. Assoc. 242:1979;2404-2405.
3. Yen S.S.C., Tsai C.C., Vandenberg G., Ribar R. Gonadotropin dynamics in patients with gonadal dysgenesis: a model for the study of gonadotropin regulation. J. Clin. Endocrinol. Metab. 35:1972;897-904.
4. Aksel S., Schomberg D.W., Tyrey L., Hammond C.B. Vasomotor symptoms, serum estrogens, and gonadotropin levels in surgical menopause. Am. J. Obstet. Gynecol. 126(2):1976;165-169.
5. Tataryn I.V., Lomax P., Bajorek J.G., Chesarek W., Meldrum D.R., Judd H.L. Postmenopausal hot flushes: a disorder of thermoregulation. Maturitas. 2(2):1980;101-107.
6. Hemminki E., Brambilla D.J., McKinlay S.M., Posner J.G. Use of estrogens among middle-aged Massachusetts women. Ann. Pharmacother. 25:1991;418-423.
7. Kronenberg F. Hot flashes: epidemiology and physiology. Ann. N. Y. Acad. Sci. 594:1990;52-86.
8. Rozenberg S., Kroll M., Vandromme J. Decision factors influencing hormone replacement therapy. Br. J. Obstet. Gynaecol. 103(13):1996;92-98.
9. Porter M., Penney G.C., Russell D., Russel E., Templeton A. A population based survey of women's experience of the menopause. Br. J. Obstet. Gynaecol. 103:1996;1025-1028.
10. Stadberg E., Mattsson L.-A., Milson I. The prevalence and severity of climacteric symptoms and the use of different treatment regimens in a Swedish population. Acta Obstet. Gynecol. Scand. 76:1997;442-448.
11. Feldman B.M., Voda A., Gromseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res. Nurs. Health. 8:1985;261-268.
12. McKinlay S.M. The normal menopause transition: an overview. Maturitas. 23(2):1996;137-145.
13. Thompson B., Hart S.A., Durno D. Menopausal age and symptomatology in a general practice. J. Biosoc. Sci. 5:1973;71-82.
14. Berg G., Gottwall T., Hammar M., Lindgren R. Climacteric symptoms among women aged 60-62 in Linkoping, Sweden, in 1986. Maturitas. 10(3):1988;193-199.
15. Mitlak B.H., Cohen F.J. Selective estrogen receptor modulators: a look ahead. Drugs. 57(5):1999;653-663.
16. Barrett-Connor E., Cox D.A., Anderson P.W. Effects of selective estrogen receptor modulators on lipids and the vasculature. The potential for protection against cardiovascular disease. Trends Endocrinol. Metab. 10(5):1999;320-325.
17. Wu X., Glinn M., Ostrowski W. et al. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase in ovariectomized rats. Brain Res. 847:1999;98-104.
18. Bryant H.U., Bales K.R., Paul S.M. et al. Estrogen agonist effects of selective estrogen receptor modulators in ovariectomized rat brain. Soc. Neurosci. 23:1997;2377. Abstract.
19. Cohen F.J., Eckert S., Mitlak B.H. Geographic differences in bone turnover: data from a multinational study in healthy postmenopausal women. Calcif. Tissue Int. 63(4):1998;277-282.
20. Delmas P., Bjarnason N.H., Mitlak B.H. et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Eng. J. Med. 337:1997;1641-1647.
21. Cox D.R. Regression models and life-tables (with discussion). J. R. Statist. Soc. B34:1972;187-220.
22. Cox D.R., Oakes D. Monographs on Statistics and Applied Probability 21: Analysis of Survival Data. 1984;37 Chapman and Hall, London.
23. McCullough P., Nelder J.A. Generalized Linear Models. 1989;193-244 Chapman and Hall, London.
24. Draper M.W., Flowers D.E., Huster W.H., Neild J.A., Harper K.D., Arnaud C. J. Bone Miner. Res. 11:1996;835-842.
25. United States Package Insert for Fareston (toremifene), December 1997.
26. United States Package Insert for Nolvadex (tamoxifen citrate), March 1996.
27. United States Package Insert for Clomid (clomiphene citrate), February 1996.
28. Ettinger B., Li D.-K., Klein R. Continuation of postmenopausal hormone replacement therapy: comparison of cyclic compared with continuous combined schedules. Menopause. 5(5):1996;185-189.
29. Salamone L.M., Pressman A.R., Seeley D.G., Cauley J.A. Estrogen replacement therapy. A survey of older women's attitudes. Arch. Intern. Med. 156:1996;1293-1297.
30. Gass M.L.S., Rebar R.W., Lui J.H., Cedars M.I. Characteristics of women who continue using hormone replacement therapy. N. Am. Menopause Soc. 4(1):1997;19-23.
31. United States Package Insert for Prempro (conjugated estrogens/medroxyprogestserone acetate USP).
32. United States Package Insert for Evista (raloxifene hydrochloride), September 30, 1999.
33. Castellsague J., Perez-Gutthann S., Garcia Rodriguez L.A. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review. Drug Saf. 18:1998;117-123.
34. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. J. Am. Med. Assoc. 282:1999;637-645.
35. Davies G.C., Huster W.J., Shen W. et al. The endometrial response to raloxifene compared with placebo, hormone replacement therapy, and unopposed estrogen in postmenopausal women. Obstet. Gynecol. 93:1999;558-565.
36. Goldstein SR, Scheele WH, Rajagopalan SR, et al. A 12-month comparative study of raloxifene, estrogen and placebo on the postmenopausal endometrium, Obstet Gynecol, in press.
37. Lufkin E.G., Whitaker M.D., Nickelsen T. et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J. Bone Miner. Res. 13:1998;1747-1754.
38. Meunier PJ, Vignot E, Garnero P, et al. for the Raloxifene Study Group. Treatment of postmenopausal osteoporosis with raloxifene, Osteoporosis Int, in press.
39. Haas S., Walsh B., Evans S., Krache M., Ravnikar V., Schiff I. The effect of transdermal estradiol on hormone and metabolic dynamics over a 6-week period. Obstet. Gynecol. 71:1988;671-676.
40. Steingold K.A., Laufer L., Chetkowski R.J. et al. Treatment of hot flashes with transdermal estradiol administration. J. Clin. Endocrinol. Metab. 61(4):1985;627-632.